Similar articles for PMID: 16959960

Year	Number of Results
1948	1
1958	1
1960	1
1977	1
1978	1
1981	2
1985	3
1990	1
1992	1
1993	1
1994	4
1995	3
1996	1
1997	5
1998	5
1999	5
2001	8
2002	5
2003	12
2004	15
2005	25
2006	37
2007	17
2008	28
2009	31
2010	31
2011	36
2012	29
2013	12
2014	9
2015	19
2016	19
2017	13
2018	18
2019	12
2020	4
2021	5
2022	2
2023	1
2024	0

1

Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells.

Jane EP, Premkumar DR, Pollack IF. Jane EP, et al. J Pharmacol Exp Ther. 2006 Dec;319(3):1070-80. doi: 10.1124/jpet.106.108621. Epub 2006 Sep 7. J Pharmacol Exp Ther. 2006. PMID: 16959960

2

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C. Liu L, et al. Cancer Res. 2006 Dec 15;66(24):11851-8. doi: 10.1158/0008-5472.CAN-06-1377. Cancer Res. 2006. PMID: 17178882

3

Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma.

Huether A, Höpfner M, Baradari V, Schuppan D, Scherübl H. Huether A, et al. Biochem Pharmacol. 2007 May 1;73(9):1308-17. doi: 10.1016/j.bcp.2006.12.031. Epub 2007 Jan 5. Biochem Pharmacol. 2007. PMID: 17266941

4

Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.

Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, Tesei A, Vannini I, Silvestrini R, Zoli W. Ulivi P, et al. J Cell Physiol. 2009 Jul;220(1):214-21. doi: 10.1002/jcp.21753. J Cell Physiol. 2009. PMID: 19288493

5

Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development.

Tran MA, Smith CD, Kester M, Robertson GP. Tran MA, et al. Clin Cancer Res. 2008 Jun 1;14(11):3571-81. doi: 10.1158/1078-0432.CCR-07-4881. Clin Cancer Res. 2008. PMID: 18519791

6

Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.

Adnane L, Trail PA, Taylor I, Wilhelm SM. Adnane L, et al. Methods Enzymol. 2006;407:597-612. doi: 10.1016/S0076-6879(05)07047-3. Methods Enzymol. 2006. PMID: 16757355

7

Rottlerin induces apoptosis via death receptor 5 (DR5) upregulation through CHOP-dependent and PKC delta-independent mechanism in human malignant tumor cells.

Lim JH, Park JW, Choi KS, Park YB, Kwon TK. Lim JH, et al. Carcinogenesis. 2009 May;30(5):729-36. doi: 10.1093/carcin/bgn265. Epub 2008 Nov 26. Carcinogenesis. 2009. PMID: 19037087

8

Effects of rottlerin, an inhibitor of calmodulin-dependent protein kinase III, on cellular proliferation, viability, and cell cycle distribution in malignant glioma cells.

Parmer TG, Ward MD, Hait WN. Parmer TG, et al. Cell Growth Differ. 1997 Mar;8(3):327-34. Cell Growth Differ. 1997. PMID: 9056675

9

Rottlerin sensitizes glioma cells to TRAIL-induced apoptosis by inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP.

Kim EH, Kim SU, Choi KS. Kim EH, et al. Oncogene. 2005 Jan 27;24(5):838-49. doi: 10.1038/sj.onc.1208241. Oncogene. 2005. PMID: 15531913

10

Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction.

Manov I, Pollak Y, Broneshter R, Iancu TC. Manov I, et al. FEBS J. 2011 Sep;278(18):3494-507. doi: 10.1111/j.1742-4658.2011.08271.x. FEBS J. 2011. PMID: 21790999 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

375 results

Results by year